Increased E-selectin in hepatic ischemia-reperfusion injury mediates liver metastasis of pancreatic cancer by Yoshimoto Katsuhiro et al.
Increased E-selectin in hepatic
ischemia-reperfusion injury mediates liver
metastasis of pancreatic cancer
著者 Yoshimoto Katsuhiro, Tajima Hidehiro, Ohta
Tetsuo, Okamoto Koichi, Sakai Seisho,
Kinoshita Jun, Furukawa Hiroyuki, Makino
Isamu, Hayashi Hironori, Nakamura Keishi,
Oyama Katsunobu, Inokuchi Masafumi, Nakagawara
Hisatoshi, Itoh Hiroshi, Fujita Hideto,
Takamura Hiroyuki, Ninomiya Itasu, Kitagawa
Hirohisa, Fushida Sachio, Fujimura Takashi,
Wakayama Tomohiko, Iseki Shoichi, Shimizu
Koichi
著者別表示 田島 秀浩, 太田 哲生, 岡本 浩一, 木下 淳, 古川
裕之, 牧野 勇, 林 泰寛, 中村 慶史, 尾山 勝信, 
井口 雅史, 中川原 寿俊, 藤田 秀人, 高村 博之, 











Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
ONCOLOGY REPORTS  28:  791-796,  2012
Abstract. Several recent studies have reported that selectins 
are produced during ischemia-reperfusion injury, and that 
selectin ligands play an important role in cell binding to the 
endothelium and in liver metastasis. Portal clamping during 
pancreaticoduodenectomy with vessel resection for pancreatic 
head cancer causes hepatic ischemia-reperfusion injury, which 
might promote liver metastasis. We investigated the liver 
colonization of pancreatic cancer cells under hepatic ischemia-
reperfusion and examined the involvement of E-selectin and 
its ligands. A human pancreatic cancer cell line (Capan-1) 
was injected into the spleen of mice after hepatic ischemia-
reperfusion (I/R group). In addition, to investigate the effect 
of an anti-E-selectin antibody on liver colonization in the IR 
group, mice received an intraperitoneal injection of the anti-
E-selectin antibody following hepatic ischemia-reperfusion 
and tumor inoculation (IR+Ab group). Four weeks later, mice 
were sacrificed and the number of tumor nodules on the liver 
was compared to mice without hepatic ischemia-reperfusion 
(control group). The incidence of liver metastasis in the I/R 
group was significantly higher (16 of 20, 80%) than that in the 
control group (6 of 20, 30%) (P<0.01). Moreover, mice in the 
I/R group had significantly more tumor nodules compared to 
those in the control group (median, 9.9 vs. 2.7 nodules) (P<0.01). 
In the I/R+Ab group, only 2 of 5 (40%) mice developed liver 
metastases. RT-PCR and southern blotting of the liver extracts 
showed that the expression of IL-1 and E-selectin mRNA after 
hepatic ischemia-reperfusion was significantly higher than 
the basal levels. Hepatic ischemia-reperfusion increases liver 
metastases and E-selectin expression in pancreatic cancer. 
These results suggest that E-selectin produced due to hepatic 
ischemia-reperfusion is involved in liver metastasis.
Introduction
Pancreatic cancer is a leading cause of cancer-related deaths 
worldwide, with a 5-year survival rate of <5% (1). For patients 
with localized disease, radical surgery with blood vessel 
resection may provide long-term benefits. However, even 
after curative resection, patients with pancreatic cancer face 
a 25-50% rate of distant metastases (2). The liver is the most 
frequent site of metastasis from pancreatic cancer. During 
hematogenous metastasis, tumor cells separate from the 
primary site, travel through the blood stream, marginate and 
adhere to the vascular endothelium, and transmigrate into 
extravascular sites where colonization occurs. Diapedesis 
of tumor cells from the circulation into secondary sites is 
believed to occur through a mechanism similar to that of 
leukocyte extravasation, in which cells must first contact and 
then roll along the endothelial cell layer. Rolling requires 
interactions between selectin cell adhesion molecules and 
their ligands (3,4). Selectin-mediated tumor cell adhesion has 
been modeled in vitro, with colorectal adenocarcinoma cells 
binding to cytokine-activated vascular endothelium (5-9). 
The fucosylated ligand components sialyl-LewisX (sLeX) 
and sialyl-LewisA (sLeA) found on the surface of circulating 
adenocarcinoma cells have been shown to bind to endothelial 
selectin (6,9-14). Studies have shown that anti-sLeX (10) and 
anti-sLeA (6,15) antibodies block adhesion of epithelial cancer 
cell lines to human umbilical vein endothelial cells (HUVEC), 
demonstrating the specificity of this interaction.
Hepatic ischemia-reperfusion always occurs during liver 
transplantation and liver resection using the Pringle method. 
During pancreaticoduodenectomy (PD) with portal vein 
resection for pancreatic cancer, portal vein clamping is used to 
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reduce intraoperative bleeding. However, this portal clamping 
causes identical hepatic ischemia-reperfusion injury. Several 
studies have shown that hepatic ischemia-reperfusion induces 
free radicals and inflammatory cytokines (16-19); therefore, 
hepatic ischemia-reperfusion may promote liver metastasis 
(20).
The major objective of this study was to investigate the 
early molecular events in liver colonization triggered by 
hepatic ischemia-reperfusion that could subsequently deter-
mine the course of metastasis.
Materials and methods
Animals. ICR nude mice weighing 20-40 g were purchased 
from Charles River Japan Inc. (Kanagawa, Japan) and were 
maintained in our Animal Care Center. All animals were 
given free access to food and water. All animal experiments 
were performed according to Guidelines for the Care and Use 
of Laboratory Animals of the Kanazawa University.
Tumor cells. The Capan-1 human pancreatic cancer cell line, 
which was isolated from a liver metastasis of a well-differ-
entiated pancreatic ductal adenocarcinoma in a 40-year-old 
Caucasian male, was obtained from the American Type Culture 
Collection (Rockville, MD, USA). This cell line was maintained 
in media supplemented with 2 mM L-glutamine, 10% fetal calf 
serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin. 
Cells were grown at 37˚C in an atmosphere of 95% air and 5% 
CO2. Tumor cells were suspended in phosphate-buffered saline 
(PBS) at a density of 2x106 cells/ml. Each mouse received an 
intrasplenic injection of 1x106 cells according to a previously 
described method (21). Cell viability was assessed with trypan 
blue prior to injection.
Treatment of animals. Mice were anesthetized with diehty-
lether, and the abdomen was incised to expose the liver. 
Total hepatic ischemia was induced by clamping the hepatic 
artery, portal vein, and bile duct. Ischemia was detected 
visually by color changes in the liver. The ischemic time 
was 20 min, which was well tolerated by the mice, and the 
reperfusion time was 15 min. The mice were divided into 2 
groups: the ischemia-reperfusion (I/R) group (n=20) and the 
control group (no ischemia-perfusion, n=20). After hepatic 
ischemia-reperfusion, 1x106 tumor cells in 0.5 ml of PBS 
were injected into the spleen of the mice. The mice were 
then closed with a 4.0 silk suture in a continuous running 
fashion. In the control group, the tumor cells were injected 
immediately after laparotomy without hepatic ischemia-
reperfusion. The animals were sacrificed 4 weeks later. The 
liver was removed and the number of tumor nodules on the 
liver surface was counted.
In addition, to test the effect of anti-E-selectin antibody 
on liver colonization, another 5 animals were inoculated with 
3 intraperitoneal injections of 100 µg of affinity-purified 
anti-E-selectin antibody at 0, 3 and 6 h after hepatic ischemia-
reperfusion and tumor inoculation. The number of tumor 
nodules was then counted (I/R+Ab group, n=5).
To determine whether hepatic ischemia-reperfusion caused 
changes in local cytokine production and E-selectin mRNA 
expression in the liver, hepatic ischemia-reperfusion was 
induced, and livers were removed at different time intervals 
(0, 0.25, 0.5, 1, 3, 6, 9, 12 and 24 h) after ischemia-reperfusion. 
IL-1, TNF-α and E-selectin mRNA levels were analyzed by 
reverse transcription-polymerase chain reaction (RT-PCR) and 
southern blotting. Liver fragments were frozen immediately in 
liquid nitrogen and stored at -80˚C until RNA extraction.
Oligonucleotide primers and probes. The sequences of the 
oligonucleotides used for RT-PCR, and southern blotting were 
as follows. IL-1 forward, 5'-CAGATTCACAACTGTTCG 
TGAGCG-3'; IL-1 and reverse primer, 5'-AAGTCTGTCA 
TAGAG GGCAGTCCC-3' (product size, 232 bp); IL-1 probe, 
5'-CACATCAGCTGCTTATCCAGAGCTG-3' (22); TNF-α 
forward, 5'-GCAGGTCTACTTTGGAGTCATTGC-3' and 
reverse primer, 5'-TCCCTTTGCAGAACTCAGGAATGG-3' 
(product size, 323 bp); TNF-α probe, 5'-TGTGCTCAGAGC 
TTTCAACAACTAC-3' (23); E-selectin forward, 5'-GTGCG 
GTGTACGTCCCTCTGGAGAAGTG-3'; and reverse primer, 
5'-TCCCTTTGCAGAACTCAGGAATGG-3' (product size, 
535 bp); E-selectin probe, 5'-TCAGAATCTACAGTGTA 
CCTCATCTG-3'; GAPDH forward, 5'-GGTGAAGGTC 
GGTGTGAACGGATTT-3' and reverse primer, 5'-AATGCC 
AAAGTTGTCATGGATGACC-3' (product size, 502 bp); and 
GAPDH probe, 5'-GTGCTGAGTATGTCGTGGAGTC 
TAC-3' (24).
RT-PCR southern blot analysis. Total cellular RNA was 
extracted from each frozen liver fragment by the acid guani-
dinium thiocyanate-phenol-chloroform method (25). The 
concentration of total RNA was determined by measuring the 
OD260. The purity of the RNA was assessed by determining 
the OD260/280 ratio, and all samples were >1.8. Aliquots of each 
total RNA sample (1 µg) were subjected to reverse transcrip-
tion (RT) at 42˚C for 60 min using Moloney murine leukemia 
virus reverse transcriptase (Toyobo Inc., Osaka, Japan). 
Subsequently, an aliquot of each RT product was amplified in 
a DNA thermal cycler (MJ Research, Inc., Watertown, MA, 
USA), using Taq DNA polymerase (Takara Bio Inc., Shiga, 
Japan) and a pair of oligonucleotide primers in a final volume 
of 100 µl. Each amplification cycle consisted of 94˚C for 1 min, 
58˚C for 2 min, and 72˚C for 1 min and 30 sec. After 25 cycles 
of amplification, each RT-PCR mixture was electrophoresed 
on a 1.5% agarose gel and blotted onto a nylon membrane (Pall 
BioSupport, East Hills, NY, USA) according to the southern 
blot procedure (26). 
An antisense oligonucleotide probe was labeled at the 3' 
end with fluorescein-11-dUTP using terminal transferase 
(Roche Diagnostics, Basel, Switzerland) and was hybridized 
to the membrane at 43˚C for 2 h in a shaking water bath 
according to the ECL 3'-oligolabelling and detection system 
protocol (Amersham Pharmacia Biotech, Uppsala, Sweden). 
After washing, the membrane was blocked with blocking solu-
tion at room temperature for 30 min, and then the membrane 
was incubated with antibody using diluted anti-fluorescein 
HRP conjugate solution containing 0.5% (w/v) bovine serum 
albumin at room temperature for 30 min. After the membrane 
was washed, the membrane was incubated with detection solu-
tion at room temperature for 10 min, and then covered with 
Saran wrap and after exposed to X-ray film (Kodak, Rochester, 
NY, USA).
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Immunocytochemical analysis of sLeA antigen on Capan-1 
cells. Capan-1 cells were suspended in RPMI-1640 medium 
on a Lab-Tek Chamber Slide (Nunc, Naperville, IL, USA) 
and incubated at 37˚C overnight in an atmosphere of 95% air 
and 5% CO2. After washing with PBS, acetone and methanol 
were added and the chamber, was incubated at 4˚C for 30 min. 
Capan-1 cells were attached to this slide, which was stored at 
-20˚C until use. Immunocytochemical staining for sLeA antigen 
was performed according to the EnVision technique (Dako, 
Glostrup, Denmark). The slide was incubated with normal 
goat serum in PBS for 30 min at room temperature, and then 
incubated with anti-human sLeA monoclonal antibody (diluted 
1:100) overnight at 4˚C. After washing with PBS, the slide was 
incubated with biotinylated anti-mouse antibody for 120 min, 
followed by the application of peroxidase-labeled streptavidin. 
The reaction product was visualized with diaminobenzidine, 
and was counterstained with hematoxylin.
Statistical analysis. The Chi-square and Mann-Whitney U 
tests were used to determine statistical significance. A P-value 
of <0.05 was considered significant.
Results
Liver colonization by Capan-1 cells after hepatic ischemia-
reperfusion. All animals in both groups survived until sacrifice. 
As shown in Table I, 16 of the 20 (80%) mice in the I/R group 
developed hepatic metastases, which was significantly higher 
than the incidence of hepatic metastases in the control group 
(6 of 20, 30%) (P<0.01). Moreover, mice in the I/R group had 
more tumor nodules than in the control group (P=0.06). The 
number of metastases per mouse in animals positive for liver 
metastasis ranged from 1 to 7 (median, 2.7) in the control 
group, and from 1 to 25 (median, 9.9) in the I/R groups (Fig. 1).
Effect of anti-E-selectin antibody on liver colonization after 
hepatic ischemia-reperfusion. As shown in Table I, injec-
tion of anti-E-selectin antibody reduced hepatic metastasis 
of Capan-1 cells. Only 2 of the 5 (40%) mice injected with 
anti-E-selectin antibody developed liver metastases and the 
metastases in the positive animals were 6 and 9, respectively.
Expression of IL-1, TNF-α and E-selectin m-RNA after 
hepatic ischemia-reperfusion. IL-1 mRNA began to increase 
30 min after ischemia-reperfusion, reached maximal levels 3 h 
after ischemia-reperfusion and decreased to basal levels 24 h 
after ischemia-reperfusion (Fig. 2). E-selectin mRNA levels 
began to rise within 1 h after ischemia-reperfusion, reached a 
maximum at 6 h, and then returned to basal levels by 24 h after 
hepatic ischemia-reperfusion. Hepatic ischemia-reperfusion 
Figure 1. The number of liver metastases in mice with hepatic ischemia-
reperfusion injury and control mice. Hepatic ischemia-reperfusion injury 
was induced in mice (I/R group), and then pancreatic cancer (Capan-1) cells 
were injected into the spleen. Control mice were injected with Capan-1 cells 
following laparotomy without ischemia-reperfusion. In the I/R group, more 
metastases per mouse were observed than in the control group.
Figure 2. Expression of IL-1, TNF-α and E-selectin mRNA after hepatic ischemia-reperfusion. IL-1, TNF-α, and E-selectin mRNA was analyzed in liver 
section extracts at the indicated time points following hepatic ischemia-reperfusion using RT-PCR and southern blotting. IL-1 and E-selectin mRNAs were 
increased after hepatic ischemia-reperfusion. However, the expression of TNF-α mRNA was not influenced by hepatic ischemia-reperfusion.
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had no significant effect on TNF-α expression at any of the 
time intervals examined (Fig. 2).
Expression of aLeA antigen on Capan-1 cells. As shown in 
Fig. 3, sLeA antigen was expressed on the surface of Capan-1 
cells.
Discussion
Tumor metastasis is a multistep process requiring detachment 
of malignant cells from the primary tumor mass, penetration 
of blood vessels, evasion of immune surveillance, attach-
ment to the endothelium of distant organs, penetration of the 
secondary tissue, and formation of new tumor colonies. The 
ability of disseminated cancer cells to establish metastases 
in secondary organs is regulated by a combination of factors 
including access to the organ microvasculature and specific 
secondary tissue-tumor cell interactions (27,28). Interaction 
between tumor cells and the secondary tissue endothelium 
is believed to be a key step in the metastatic cascade (29), 
and is thought to be mediated by adhesion receptor-ligand 
pairs, some of which are involved in physiological leukocyte-
endothelial interactions (30). The various combinations of 
cell surface molecules expressed by tumor cells may serve as 
ligands for endothelial cell surface receptors (5,10,11,31,32), 
which are typically induced by mediators of inflammation 
(5,31,32). Therefore, a local inflammatory response may 
facilitate circulating tumor cell adhesion and arrest. Takada 
et al (9) showed that epithelial cancer cells have the ability to 
adhere to endothelial cells, and that their adhesion is enhanced 
by activation of endothelial cells with cytokines such as IL-1. 
They also showed that E-selectin (endothelial leukocyte adhe-
sion molecule -1: ELAM-1), first introduced as an adhesion 
molecule that mediates leukocyte adhesion to endothelial cells 
(33), is of particular importance in the adhesion of human 
epithelial cancer cells to vascular endothelial cells.
E-selectin is an adhesion molecule that is not expressed 
on normal endothelial cells. However, E-selectin is transiently 
expressed on the surface of vascular endothelium after stimu-
lation with IL-1 and TNF-α, and has been implicated in the 
initial events of neutrophil extravasation in the inflammatory 
response. E-selectin also appears to be involved in tumor inva-
sion and metastasis, since E-selectin mediates adherence of 
leukemia and colon cancer cells to activated endothelial cells. 
Several studies have implicated E-selectin in the adhesion 
of cancer cells to vascular endothelial cells (6,8,10,34,35). 
It has been suggested that E-selectin is involved in the pref-
erential homing of metastasizing cells to the liver (36), and 
that E-selectin mediates the metastasis of certain tumor types 
(36,37). Uotani et al reported that induction of E-selectin after 
partial hepatectomy promotes liver metastasis in mice (38).
We examined the expression of cytokines, such as IL-1 and 
TNF-α, and E-selectin by RT-PCR and southern blotting after 
hepatic ischemia-reperfusion. Our results showed maximum 
expression of E-selectin mRNA 6 h after hepatic ischemia-
reperfusion, with a return to baseline levels by 24 h after 
ischemia-reperfusion. This finding is consistent with previous 
reports (38,39).
In liver surgery for pancreatic cancer with portal resec-
tion, temporary hepatic pedicle clamping has been used to 
reduce intraoperative bleeding since the report by Pringle 
(40). However, this clamping causes ischemia-reperfusion 
injury (19,41), and ischemia-reperfusion injury elicits endo-
thelial cell injury that can manifest as swelling, detachment 
from the underlying basement membrane, and compromised 
barrier function. These events might be accompanied by 
leukocyte-endothelial cell adhesion, which manifest as 
rolling, firm adhesion, and emigration of leukocytes in post-
capillary venules of the microvasculature (42). Several studies 
have reported that hepatic ischemic-reperfusion induces free 
radicals and inflammatory cytokines (16-19). Free radicals 
and cytokines, such as TNF-α and IL-1 are implicated in the 
acceleration of hepatic metastasis, and therefore it is possible 
that hepatic ischemia-reperfusion promotes liver metastasis 
(20). Our study verified that hepatic ischemia-reperfusion 
promotes liver metastasis of Capan-1 cells; the number of 
tumor nodules in the I/R group was significantly greater than 
that in the control group. We also found that administration 
of an anti-E-selectin monoclonal antibody to mice in the I/R 
group after tumor inoculation inhibited liver metastasis. This 
finding is supported by previous reports which demonstrated 
that a neutralizing murine E-selectin monoclonal antibody 
abrogated hepatic metastasis in vivo (36,38).
The sialylated, fucosylated tetrasaccharides LeX and sLeA 
and related carbohydrate structures, have been identified as 
selectin ligands (6,9-14,34). Interestingly, sLeX and sLeA have 
also been identified as markers of progression in several types 
Figure 3. Immunocytochemical staining for siayl-LewisA antigen (sLeA) in 
the Capan-1 pancreatic cancer cell line. SLeA antigen was expressed on the 
cell surface of Capan-1 cells.
Table I. Incidence of liver metastasis in control mice  and in 
mice with hepatic ischemia-reperfusion injury treated or not 
treated with the anti-E-selectin antibody.
 I/R group Control group I/R+Ab group
 (n=20) (n=5) (n=20)
Liver metastasis (+) 16 6 2
Incidence 80% 30% 40%
P<0.01, control group vs. the I/R group.
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of carcinoma, particularly carcinomas of the gastrointestinal 
tract, which commonly metastasize to the liver (43,44). 
In vitro adhesion studies have shown that carbohydrate deter-
minants adhere to TNF-α-inducible E-selectin on HUVECs 
(6-9,13,36).
Our study showed that sLeA was expressed on the surface 
of Capan-1 cells. It has been reported that sLeA on pancre-
atic carcinoma cells is an important ligand for E-selectin on 
activated endothelial cells (15,45). These results suggested 
that sLeA expression on pancreatic carcinoma cell lines might 
modulate events related to carcinoma cell-to-endothelial cell 
attachment, thereby contributing to hematogenous metas-
tasis in vivo (46). A recent study reported that intermittent 
hepatic ischemia-reperfusion preconditioning minimizes 
liver metastasis (47). The usefulness of intermittent hepatic 
ischemia-reperfusion preconditioning in Pringle's method for 
hepatectomy is well known (16-19,40). During PD with portal 
vein resection and reconstruction, portal vein clamping is 
necessary to reduce intraoperative bleeding. However, portal 
vein clamping-unclamping causes ischemia-reperfusion of the 
liver, but congestion-re-outflow in the small intestine. To avoid 
congestion of the small intestine, we have been using small 
intestinal ischemic preconditioning by clamping the superior 
mesenteric artery (SMA) during portal vein clamping in PD 
with portal vein resection. We have reported that small intes-
tinal ischemia-reperfusion injury was reduced by ischemic 
preconditioning induced by clamping the SMA (48). Small 
intestinal ischemic preconditioning by clamping the SMA 
could suppress the increase in cytokines and reduce undesir-
able liver metastasis from pancreatic cancer due to surgical 
procedures such as intraoperative portal vein clamping.
In conclusion, hepatic ischemia-reperfusion causes 
increased liver metastases as well as increased expression 
of E-selectin, which has been reported to mediate metastasis 
of cancer cells that express sLeA. Agents that interfere with 
hepatic E-selectin induction and/or function might have thera-
peutic, anti-metastatic effects during the early stages of liver 
colonization.
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